Texas is listed as the third-most vulnerable state when it comes to robots replacing the workforce in manufacturing. Houston houses a third of the manufacturing jobs in the state. Thossaphol Somsri/Getty Images

If a new forecast comes true, Houston's manufacturing sector could take an especially hard hit from the upturn in the use of robots.

In a new report, Oxford Economics, a forecasting and analysis firm based in the United Kingdom, ranks Texas as the third most vulnerable state when it comes to human workers in manufacturing being replaced by robotic labor. The report gives no estimate of how many manufacturing jobs Texas might lose to robots, but around the world, robots could boot 20 million jobs by 2030.

About one-third of Texas' manufacturers operate in the Houston metro area, meaning the robot revolution carries significant weight for the regional economy.

In 2017, manufacturing accounted for $82.6 billion, or nearly 17 percent, of the Houston area's economic output, the U.S. Bureau of Economic Analysis says. Manufacturing employment in the region averaged 219,160 jobs in 2017, with total wages of nearly $4.8 billion.

Among the top manufacturing segments in the region are fabricated metals (22 percent of all manufacturing jobs), machinery (19 percent) and chemicals (17.5 percent), according to the Greater Houston Partnership. Between 2012 and 2017, manufacturing employment in the Houston area slipped by 9.8 percent, going from 243,011 workers to 219,160 workers.

However, a recent report from the Economic Innovation Group shows Harris County netted more manufacturing jobs (11,592) from December 2016 to December 2018 than any other county in the U.S.

According to the National Association of Manufacturers, the manufacturing sector in Texas created more than $226 billion in economic output in 2017. Last year, about 880,900 people held manufacturing jobs in Texas; that's more than 7 percent of the statewide workforce.

In declaring that Texas sits among the states most susceptible to job losses due to robotics, Oxford Economics took into account factors such as:

  • Dependence on manufacturing jobs.
  • Current use of robots in manufacturing.
  • Productivity of the manufacturing workforce.

Based on those criteria, Texas received a robot vulnerability score of 0.50. The top two states, Oregon and Louisiana, each got a score of 0.58, with the higher number meaning greater vulnerability.

The report cites three reasons for the ascent of robots in manufacturing:

  • Robots are becoming cheaper than humans.
  • Robots are becoming more sophisticated.
  • Demand for manufactured goods is rising.

"The rise of the robots will boost productivity and economic growth. It will lead, too, to the creation of new jobs in yet-to-exist industries, in a process of 'creative destruction,'" according to the Oxford Economics report. "But existing business models across many sectors will be seriously disrupted. And tens of millions of existing jobs will be lost, with human workers displaced by robots at an increasing rate as robots become steadily more sophisticated."

Tony Bennett, president and CEO of the Texas Association of Manufacturers, says the Oxford Economics report isn't all gloom and doom.

"Robotics and mechanization in our advanced manufacturing industries will continue to displace some general-labor jobs. However, this change is also ushering in a new set of higher-skilled jobs that are being created to engineer, build, and service these sophisticated machines," Bennett says. "The state of Texas must continue striving to increase educational opportunities in engineering, math, science, and career and technical programs to meet the complex manufacturing processes of the future."

Houston Community College's Advanced Manufacturing Center for Excellence is among the organizations in the Houston area that are preparing workers for jobs in robotics and other high-demand, tech-driven aspects of manufacturing.

"Innovation is Houston's bedrock," Houston Mayor Sylvester Turner said in 2017. "The city would have never thrived without the innovations it took to build the Ship Channel and the innovating that goes on every day in the energy industry, at the Texas Medical Center, at the Johnson Space Center and in the manufacturing sector. Now, Houston is poised to take its place at the forefront of the American future in technology."

Earlier this year, another study found a similarly daunting result. Almost half of Houston's workplace tasks are susceptible to automation, according to a new report from the Brookings Institution's Metropolitan Policy Program. Of 100 metros analyzed, Houston ranks 31st among the country's 100 biggest metros, with 46.3 percent of work tasks susceptible to automation.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston biotech company tests hard-to-fight cancer therapeutics

fighting cancer

A Houston-based, female-founded biotech company has developed a treatment that could prove to be an effective therapy for a rare blood cancer.

Cellenkos Therapeutics has completed promising Phase 1b testing of its Treg cell therapy, CK0804, in the fight against myelofibrosis. According to a news release from the Cellenkos team, the use of its cord-blood-derived therapeutics could signal a paradigm shift for the treatment of this hard-to-fight cancer.

Cellenkos was founded by MD Anderson Cancer Center physician and professor Simrit Parmar. Her research at the hospital displayed the ability of a unique subset of T cells’ capability to home in on a patient’s bone marrow, restoring immune balance, and potentially halting disease progression.

Myelofibrosis has long been treated primarily with JAK (Janus Kinase) inhibitors, medications that help to block inflammatory enzymes. They work by suppressing the immune response to the blood cancer, but don’t slow the progression of the malady. And they’re not effective for every patient.

“There is a significant need for new therapeutic options for patients living with myelofibrosis who have suboptimal responses to approved JAK inhibitors,” Parmar says. “We are greatly encouraged by the safety profile and early signs of efficacy observed in this patient cohort and look forward to continuing our evaluation of the clinical potential of CK0804 in our planned expansion cohort.”

The expansion cohort is currently enrolling patients with myelofibrosis. What exactly are sufferers dealing with? Myelofibrosis is a chronic disease that causes bone marrow to form scar tissue. This makes it difficult for the body to produce normal blood cells, leaving patients with fatigue, spleen enlargement and night sweats.

Myelofibrosis is rare, with just 16,000 to 18,500 people affected in the United States. But for patients who don’t respond well to JAKs, the prognosis could mean a shorter span than the six-year median survival rate outlined for the disease by Cleveland Clinic.

Helping myelofibrosis patients to thrive isn’t the only goal for Cellenkos right now.

The company seeks to aid people with rare conditions, particularly inflammatory and autoimmune disorders, with the use of CK0804, but also other candidates including one known as CK0801. The latter drug has shown promising efficacy in aplastic anemia, including transfusion independence in treated patients.

The company closed its $15 million series A round led by BVCF Management, based in Shanghai, in 2021. Read more here.

Pioneering Houston biotech startup expands to Brazil for next phase

On the Move

Houston biotech company Cemvita has expanded into Brazil. The company officially established a new subsidiary in the country under the same name.

According to an announcement made earlier this month, the expansion aims to capitalize on Brazil’s progressive regulatory framework, including Brazil’s Fuel of the Future Law, which was enacted in 2024. The company said the expansion also aims to coincide with the 2025 COP30, the UN’s climate change conference, which will be hosted in Brazil in November.

Cemvita utilizes synthetic biology to transform carbon emissions into valuable bio-based chemicals.

“For decades Brazil has pioneered the bioeconomy, and now the time has come to create the future of the circular bioeconomy,” Moji Karimi, CEO of Cemvita, said in a news release. “Our vision is to combine the innovation Cemvita is known for with Brazil’s expertise and resources to create an ecosystem where waste becomes opportunity and sustainability drives growth. By joining forces with Brazilian partners, Cemvita aims to build on Brazil’s storied history in the bioeconomy while laying the groundwork for a circular and sustainable future.”

The Fuel of the Future Law mandates an increase in the biodiesel content of diesel fuel, starting from 15 percent in March and increasing to 20 percent by 2030. It also requires the adoption of Sustainable Aviation Fuel (SAF) and for domestic flights to reduce greenhouse gas emissions by 1 percent starting in 2027, growing to 10 percent reduction by 2037.

Cemvita agreed to a 20-year contract that specified it would supply up to 50 million gallons of SAF annually to United Airlines in 2023.

"This is all made possible by our innovative technology, which transforms carbon waste into value,” Marcio Da Silva, VP of Innovation, said in a news release. “Unlike traditional methods, it requires neither a large land footprint nor clean freshwater, ensuring minimal environmental impact. At the same time, it produces high-value green chemicals—such as sustainable oils and biofuels—without competing with the critical resources needed for food production."

In 2024, Cemvita became capable of generating 500 barrels per day of sustainable oil from carbon waste at its first commercial plant. As a result, Cemvita quadrupled output at its Houston plant. The company had originally planned to reach this milestone in 2029.

---

This story originally appeared on our sister site, EnergyCapitalHTX.